| Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers (NCT02153437) | Bristol-Myers Squibb | 2014-10-30 |
| Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) (NCT02231749) | Bristol-Myers Squibb | 2014-10-16 |
| Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin (NCT02279732) | Bristol-Myers Squibb | 2014-10-13 |
| A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) (NCT02156804) | Bristol-Myers Squibb | 2014-10-07 |
| Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4) (NCT02227459) | Bristol-Myers Squibb | 2014-10-01 |
| Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the US (NCT02674594) | Bristol-Myers Squibb | 2014-10-01 |
| A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects (NCT02293629) | Bristol-Myers Squibb | 2014-10-01 |
| Japanese Bridging Study Conducted in the United States (NCT00947245) | Bristol-Myers Squibb | 2014-10-01 |
| Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects (NCT02327273) | Bristol-Myers Squibb | 2014-10-01 |
| Safety Profile of Nulojix in Home Infusion Settings (NCT02500498) | Bristol-Myers Squibb | 2014-10-01 |
| Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C (NCT02250001) | Bristol-Myers Squibb | 2014-09-30 |
| An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma (NCT02253992) | Bristol-Myers Squibb | 2014-09-29 |
| Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects (NCT02257151) | Bristol-Myers Squibb | 2014-09-01 |
| Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES) (NCT02661568) | Bristol-Myers Squibb | 2014-09-01 |
| Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects (NCT02341638) | Bristol-Myers Squibb | 2014-09-01 |
| A Phase 1 Drug-drug Interaction Study in Healthy Volunteers (NCT02227173) | Bristol-Myers Squibb | 2014-09-01 |
| Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) (NCT02181738) | Bristol-Myers Squibb | 2014-08-12 |
| Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan (NCT02335606) | Bristol-Myers Squibb | 2014-08-06 |
| Impact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir (NCT02532673) | Bristol-Myers Squibb | 2014-08-01 |
| A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects (NCT02211469) | Bristol-Myers Squibb | 2014-08-01 |
| Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120 (NCT02208882) | Bristol-Myers Squibb | 2014-08-01 |
| A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark (NCT02591732) | Bristol-Myers Squibb | 2014-08-01 |
| Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) (NCT02175966) | Bristol-Myers Squibb | 2014-07-28 |
| A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation (NCT02156076) | Bristol-Myers Squibb | 2014-07-25 |
| Eliquis Regulatory Post Marketing Surveillance (rPMS) (NCT01885585) | Bristol-Myers Squibb | 2014-07-01 |
| Clinical and Economic Burden of Bleeding Events in Patients in the UK With Non-valvular Atrial Fibrillation Treated With Vitamin k Antagonists (NCT02661516) | Bristol-Myers Squibb | 2014-07-01 |
| Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects (NCT02164812) | Bristol-Myers Squibb | 2014-07-01 |
| A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure (NCT02157506) | Bristol-Myers Squibb | 2014-06-30 |
| A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 (NCT02170727) | Bristol-Myers Squibb | 2014-06-26 |
| Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2 (NCT02488421) | Bristol-Myers Squibb | 2014-06-01 |
| Expanded Access Program With Nivolumab to Treat Melanoma (NCT02142218) | Bristol-Myers Squibb | 2014-06-01 |
| Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden (NCT02492828) | Bristol-Myers Squibb | 2014-06-01 |
| Study of Drug Combination on Pharmacokinetics in Healthy Volunteers (NCT02175602) | Bristol-Myers Squibb | 2014-06-01 |
| Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients (NCT01797848) | Bristol-Myers Squibb | 2014-06-01 |
| Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants (NCT02159352) | Bristol-Myers Squibb | 2014-06-01 |
| Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) (NCT02105636) | Bristol-Myers Squibb | 2014-05-29 |
| Interferon Toxicities in Melanoma Treatment (NCT02794636) | Bristol-Myers Squibb | 2014-05-01 |
| Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects (NCT02079480) | Bristol-Myers Squibb | 2014-05-01 |
| A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes (NCT02097277) | Bristol-Myers Squibb | 2014-04-15 |
| A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen (NCT02066636) | Bristol-Myers Squibb | 2014-04-09 |
| Absolute Bioavailability of BMS-791325 (NCT02112110) | Bristol-Myers Squibb | 2014-04-01 |
| Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer (NCT02110082) | Bristol-Myers Squibb | 2014-04-01 |
| UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C (NCT02123654) | Bristol-Myers Squibb | 2014-04-01 |
| Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis (NCT01666704) | Bristol-Myers Squibb | 2014-04-01 |
| Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325 (NCT02103569) | Bristol-Myers Squibb | 2014-04-01 |
| Early Post-marketing Study of Eliquis (Apixaban) (NCT02153424) | Bristol-Myers Squibb | 2014-04-01 |
| To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet (NCT02108639) | Bristol-Myers Squibb | 2014-04-01 |
| Suicidality and Suicide Attempt Among HIV Patients on Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens (NCT02211807) | Bristol-Myers Squibb | 2014-04-01 |
| Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects (NCT02084953) | Bristol-Myers Squibb | 2014-04-01 |
| Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325 (NCT02095860) | Bristol-Myers Squibb | 2014-04-01 |
| Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin (NCT02104843) | Bristol-Myers Squibb | 2014-04-01 |
| An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) (NCT02041533) | Bristol-Myers Squibb | 2014-03-27 |
| Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) (NCT02038946) | Bristol-Myers Squibb | 2014-03-26 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (NCT02061761) | Bristol-Myers Squibb | 2014-03-13 |
| A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (NCT02060188) | Bristol-Myers Squibb | 2014-03-12 |
| Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients (NCT02159365) | Bristol-Myers Squibb | 2014-03-08 |
| Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) (NCT02038933) | Bristol-Myers Squibb | 2014-03-05 |
| Bioavailability of Apixaban Crushed Tablet (NCT02101112) | Bristol-Myers Squibb | 2014-03-01 |
| Drug Interaction Study With Rosuvastatin (NCT02101125) | Bristol-Myers Squibb | 2014-03-01 |
| Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant (NCT02032875) | Bristol-Myers Squibb | 2014-03-01 |
| Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020 (NCT02068053) | Bristol-Myers Squibb | 2014-03-01 |
| Drug Interaction Statin (NCT02089061) | Bristol-Myers Squibb | 2014-03-01 |
| Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual (NCT01995266) | Bristol-Myers Squibb | 2014-02-28 |
| A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (NCT02017717) | Bristol-Myers Squibb | 2014-02-07 |
| A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia (NCT02011945) | Bristol-Myers Squibb | 2014-02-07 |
| Drug Interaction & Methadone & Buprenorphine (NCT02045693) | Bristol-Myers Squibb | 2014-02-01 |
| Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects (NCT02045966) | Bristol-Myers Squibb | 2014-02-01 |
| Ipilimumab 12-month Intensive Pharmacovigilance Protocol (NCT02050594) | Bristol-Myers Squibb | 2014-02-01 |
| A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects (NCT02074358) | Bristol-Myers Squibb | 2014-02-01 |
| A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers (NCT02819271) | Bristol-Myers Squibb | 2014-02-01 |
| Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population (NCT02363868) | Bristol-Myers Squibb | 2014-02-01 |
| A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. (NCT02032888) | Bristol-Myers Squibb | 2014-02-01 |
| Post-marketing Study Assessing the Long-Term Safety of Abatacept (NCT02169544) | Bristol-Myers Squibb | 2014-01-31 |
| Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response (NCT01850004) | Bristol-Myers Squibb | 2014-01-22 |
| APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study (NCT02640222) | Bristol-Myers Squibb | 2014-01-01 |
| To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers (NCT02017730) | Bristol-Myers Squibb | 2014-01-01 |
| Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV (NCT02032901) | Bristol-Myers Squibb | 2014-01-01 |
| UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects (NCT01979939) | Bristol-Myers Squibb | 2013-12-01 |
| Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients (NCT01990859) | Bristol-Myers Squibb | 2013-12-01 |
| UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis (NCT01973049) | Bristol-Myers Squibb | 2013-12-01 |
| A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects (NCT03197779) | Bristol-Myers Squibb | 2013-11-18 |
| An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors (NCT01968109) | Bristol-Myers Squibb | 2013-11-05 |
| Japanese Phase 1 Study of BMS-844203 (CT322) (NCT01146171) | Bristol-Myers Squibb | 2013-11-01 |
| Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors (NCT01986218) | Bristol-Myers Squibb | 2013-11-01 |
| PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma (NCT02492815) | Bristol-Myers Squibb | 2013-10-31 |
| A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (NCT01928394) | Bristol-Myers Squibb | 2013-10-24 |
| Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) (NCT01884350) | Bristol-Myers Squibb | 2013-10-15 |
| Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela (NCT02756481) | Bristol-Myers Squibb | 2013-10-01 |
| PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy) (NCT01891643) | Bristol-Myers Squibb | 2013-09-30 |
| Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL (NCT02600455) | Bristol-Myers Squibb | 2013-09-01 |
| Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg (NCT02600468) | Bristol-Myers Squibb | 2013-09-01 |
| Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation (NCT02007655) | Bristol-Myers Squibb | 2013-09-01 |
| Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) (NCT01844518) | Bristol-Myers Squibb | 2013-08-30 |
| Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (NCT01927419) | Bristol-Myers Squibb | 2013-08-23 |
| Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan (NCT01835470) | Bristol-Myers Squibb | 2013-08-09 |
| Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV (NCT01866930) | Bristol-Myers Squibb | 2013-07-11 |
| Eliquis Regulatory Post Marketing Surveillance (NCT01885598) | Bristol-Myers Squibb | 2013-07-10 |
| Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe (NCT01890473) | Bristol-Myers Squibb | 2013-07-01 |
| Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes (NCT01864174) | Bristol-Myers Squibb | 2013-06-20 |
| Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis (NCT01860976) | Bristol-Myers Squibb | 2013-06-17 |